<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002948</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065416</org_study_id>
    <secondary_id>YALE-HIC-9042</secondary_id>
    <secondary_id>NCI-G97-1155</secondary_id>
    <nct_id>NCT00002948</nct_id>
  </id_info>
  <brief_title>High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer</brief_title>
  <official_title>A Phase I Study of High Dose Topotecan With Filgrastim and Peripheral Blood Stem Cell Support for Patients With Refractory Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of high-dose topotecan and peripheral stem&#xD;
      cell transplantation in treating patients with refractory cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose, toxicities, and preliminary antitumor activity of&#xD;
           escalating doses of topotecan, with filgrastim (G-CSF) and peripheral blood stem cell&#xD;
           support, when administered to patients with refractory malignancies for which no&#xD;
           effective therapy exists.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Prior to stem cell harvesting, patients receive 1-2 courses of mobilizing salvage&#xD;
      chemotherapy.&#xD;
&#xD;
      After stem cell harvest, high-dose topotecan is administered according to an escalating&#xD;
      dosage scale. Topotecan is given over 30 minutes daily for three days. A minimum of 3&#xD;
      patients are entered at each dose level. The MTD is defined as the dose immediately below&#xD;
      that at which 2 patients experience dose limiting toxicity.&#xD;
&#xD;
      Peripheral blood stem cells (PBSC) are infused at least 24 hours after treatment with&#xD;
      topotecan is complete. Filgrastim (G-CSF) is administered subcutaneously beginning on the day&#xD;
      PBSC are infused and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Not specified&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 1996</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed refractory malignancies for which no effective therapy is&#xD;
             currently available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Total bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No chronic active hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Left ventricular ejection fraction greater than 45%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO greater than 60% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No concurrent medical condition that would preclude therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or&#xD;
             mitomycin)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No radiotherapy to greater than 30% of bone marrow&#xD;
&#xD;
          -  No wide field radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from any prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

